2020
DOI: 10.1007/s12471-020-01375-4
|View full text |Cite
|
Sign up to set email alerts
|

Outcome of mechanical circulatory support at the University Medical Centre Utrecht

Abstract: Background The prevalence of heart failure (HF) is increasing substantially and, despite improvements in medical therapy, HF still carries a poor prognosis. Mechanical circulatory support (MCS) by a continuousflow left ventricular assist device (cf-LVAD) improves survival and quality of life in selected patients. This holds especially for the short-term outcome, but experience regarding long-term outcome is growing as the waiting time for heart transplantation is increasing due to the shortage of donor hearts.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 7 publications
(11 citation statements)
references
References 27 publications
0
11
0
Order By: Relevance
“…1 Because of a shortage of donor hearts, long-term left ventricular assist devices (LVADs) have become an established therapeutic option for these patients, with a 1 year survival of~80%. 2,3 Even though the use of mechanically circulatory support (MCS) results in improved survival rates, patients often suffer from major complications. Only 20% of the patients are not readmitted to the hospital within the first year after primary implantation.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…1 Because of a shortage of donor hearts, long-term left ventricular assist devices (LVADs) have become an established therapeutic option for these patients, with a 1 year survival of~80%. 2,3 Even though the use of mechanically circulatory support (MCS) results in improved survival rates, patients often suffer from major complications. Only 20% of the patients are not readmitted to the hospital within the first year after primary implantation.…”
Section: Introductionmentioning
confidence: 99%
“…Heart transplantation (HTx) is the gold standard for patients with end‐stage heart failure 1 . Because of a shortage of donor hearts, long‐term left ventricular assist devices (LVADs) have become an established therapeutic option for these patients, with a 1 year survival of ~80% 2,3 . Even though the use of mechanically circulatory support (MCS) results in improved survival rates, patients often suffer from major complications.…”
Section: Introductionmentioning
confidence: 99%
“…Already 50-70% of the patients receiving heart transplants have had an LVAD implanted first and the expectation is that this percentage will grow even further. If the number of available donor hearts does not increase substantially, given the current promising short-and medium-term outcome after LVAD implantation, the surgical treatment of advanced heart failure will change considerably in the coming years [5].…”
Section: Mcs and Heart Transplantationmentioning
confidence: 99%
“…MCS is becoming more and more important in the treatment of advanced heart failure and the mid-term outcome with regard to survival and functional recovery is approaching that of heart transplantation [5][6][7][8], although it is a very laborious and expensive therapy [9,10]. In the near future MCS will be used more and more as an alternative to transplantation, and this will certainly have a huge impact on the selection of transplant candidates.…”
Section: Introductionmentioning
confidence: 99%
“…Following LVAD implantation, not only survival, but also quality of life and exercise capacity improves impressively, allowing a return to a normal life, including sports activities and even resumption of work [ 18 20 ]. Despite this promising survival, morbidity after LVAD implantation remains substantial, as was confirmed in a recent publication showing major bleeding and ventricular tachycardia as the most commonly encountered adverse events [ 21 ].
Fig.
…”
Section: Survivalmentioning
confidence: 99%